Trial Profile
Double-blind, placebo-controlled, parallel-group, randomized multicentre study to assess the efficacy and safety of LAIS Ragweed Sublingual tablet in patients with allergic rhinoconjunctivitis to ragweed pollen
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Lofarma S.p.A
- 10 Mar 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 01 Apr 2015 New trial record